Tuesday, August 18, 2020
Hematology-Oncology news:
- Chemo-free management of mesothelioma on horizon: https://bit.ly/2CyL6xY
CheckMate 743: https://bit.ly/2CBy6HX
INITIATE trial: https://bit.ly/3axxdg8
MAPS2: https://bit.ly/32hWCa0 - FDA approves first liquid biopsy/NGS test for lung cancer: https://bit.ly/3258jRn
- Swallowable 'sponge on a string' to diagnose esophageal cancer: https://bit.ly/3iUbLFb
Source: https://bit.ly/2Q0T6en - COVID-19 impact: Less chemo, immune checkpoint inhibitors, and steroids: https://bit.ly/2Ebwmpq
Survey: https://bit.ly/3h14S4h
Email Blood & Cancer: podcasts@mdedge.com
How to Listen
Podcast Participants
David Henry, MD, FACP, is a clinical professor of medicine at the University of Pennsylvania and vice chairman of the department of medicine at Pennsylvania Hospital in Philadelphia. He received his bachelor’s degree from Princeton University and his MD from the University of Pennsylvania, then completed his internship, residency, and fellowship at the Hospital of the University of Pennsylvania. After 2 years as an attending in the U.S. Air Force, he was drawn to practicing as a hem-onc because of the close patient contact and interaction, and his belief that, win or lose with each patient, one can always make a difference in their care and lives. Follow Dr. Henry on Twitter: @davidhenrymd. Dr. Henry reported being on the advisory board for Amgen, AMAG Pharmaceuticals, and Pharmacosmos. He reported institutional funding from the National Institutes of Health and FibroGen.